The positive correlation between Aurora A and c-Myc expression in primary CML samples suggests that blocking Aurora kinase activity in combination with ABL TKI treatment can decrease the proliferation and survival of Ph+ cells as a result of c-Myc downregulation. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.